Cystic Fibrosis has seen dramatic advances in treatment since the last edition, including targeted cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators for most CFTR gene abnormalities. This new 5th edition is an update of the rapid clinical and scientific advances in improving prognosis, and the impact of CoVID-19, which has transformed conventional models of care. It covers basic science, such as how detailed understanding of the biology of the CFTR gene and protein has led to novel and beneficial therapies, as well as all aspects of clinical management in high-, middle- and low-income settings, and the voices of patients from across the world. It will be a useful reference for clinicians across the whole multidisciplinary team, scientists, and students. Key Features: • Follows an appealing organisation of chapters, by developing fundamental knowledge of the reader before moving on to more complex or developing topics. • Presents a comprehensive, authoritative, and up-to-date text, integrating basic science and clinical aspects of Cystic Fibrosis with a wealth of accompanying high quality videos, providing an attractive read for clinicians, trainee doctors, and scientists. • Draws on global expertise and reflects best evidence-based practice from experts doing cutting edge clinical and basic science research from around the world.